TPSB2 and urogenital neoplasm: The suppression of mast cell tryptase (TPSB2), an indicator of mast cell degranulation, also confirmed the therapeutic potential of DFO and EDA in inhibiting mast cell activation of prostatitis (Figure 7(c)).